A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
Identifieur interne : 002B90 ( PascalFrancis/Curation ); précédent : 002B89; suivant : 002B91A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
Auteurs : P. A. Vasey [Royaume-Uni, Australie] ; M. Gore [Royaume-Uni] ; R. Wilson [Royaume-Uni] ; G. Rustin [Royaume-Uni] ; H. Gabra [Royaume-Uni] ; J-P. Guastalla [France] ; E. P. Lauraine [France] ; J. Paul [Royaume-Uni] ; K. Carty [Royaume-Uni] ; S. Kaye [Royaume-Uni]Source :
- British journal of cancer [ 0007-0920 ] ; 2008.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
The safety and maximum tolerated dose (MTD) of erlotinib with docetaxel/carboplatin were assessed in patients with ovarian cancer. Chemonaive patients received intravenous docetaxel (75 mg m-2) and carboplatin (area under the curve 5) on day I of a 3-week cycle, and oral erlotinib at 50 (cohort 1), 100 (cohort 2a) or 75 mg day-1 (cohort 2b) for up to six cycles. Dose-limiting toxicities were determined in cycle 1. Forty-five patients (median age 59 years) received treatment. Dose-limiting toxicities occurred in 1/5/5 patients (cohorts I /2a/2b). The MTD of erlotinib in this regimen was determined to be 75 mg day-1 (cohort 2b; the erlotinib dose was escalated to 100mg day-1 in I I out of 19 patients from cycle 2 onwards). Neutropaenia was the predominant grade 3/4 haematological toxicity (85/100/95% respectively). Common non-haematological toxicities were diarrhoea, fatigue, nausea and rash. There were five complete and seven partial responses in 23 evaluable patients (52% response rate). Docetaxel/carboplatin had no measurable effect on erlotinib pharmacokinetics. In subsequent single-agent maintenance, erlotinib was given at 100-150 mg day-1, with manageable toxicity, until tumour progression. Further investigation of erlotinib in epithelial ovarian carcinoma may be warranted, particularly as maintenance therapy.
| pA |
|
|---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003459
Links to Exploration step
Pascal:08-0315574Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers</title><author><name sortKey="Vasey, P A" sort="Vasey, P A" uniqKey="Vasey P" first="P. A." last="Vasey">P. A. Vasey</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>CR-UK Clinical Triais Unit, Beatson Oncology Centre, Western Infirmary, Dumbarton Road</s1><s2>Glasgow, Scotland GI 1 6NT</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Medicine, University of Queensland</s1><s2>Brisbane Q4029</s2><s3>AUS</s3><sZ>1 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Gore, M" sort="Gore, M" uniqKey="Gore M" first="M." last="Gore">M. Gore</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Royal Marsden Hospital, Fulham Road</s1><s2>London SW15 3SW</s2><s3>GBR</s3><sZ>2 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Wilson, R" sort="Wilson, R" uniqKey="Wilson R" first="R." last="Wilson">R. Wilson</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Belfast City Hospital, Lisbum Road</s1><s2>Belfast, Ireland BT9 7AB</s2><s3>GBR</s3><sZ>3 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Rustin, G" sort="Rustin, G" uniqKey="Rustin G" first="G." last="Rustin">G. Rustin</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Mount Vernon Hospital, Rickmansworth Road</s1><s2>Northwood, Hertfordshire HA6 2RN</s2><s3>GBR</s3><sZ>4 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Gabra, H" sort="Gabra, H" uniqKey="Gabra H" first="H." last="Gabra">H. Gabra</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Western General Hospital, Crewe Road South</s1><s2>Edinburgh, Scotland EH4 2XU</s2><s3>GBR</s3><sZ>5 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Guastalla, J P" sort="Guastalla, J P" uniqKey="Guastalla J" first="J-P." last="Guastalla">J-P. Guastalla</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Centre Léon-Bérard, rue Laennec</s1><s2>69373, Lyon</s2><s3>FRA</s3><sZ>6 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Lauraine, E P" sort="Lauraine, E P" uniqKey="Lauraine E" first="E. P." last="Lauraine">E. P. Lauraine</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Hopital de L'Hotel-Dieu, place du Parvis Notre-Dame</s1><s2>75181 Paris</s2><s3>FRA</s3><sZ>7 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Paul, J" sort="Paul, J" uniqKey="Paul J" first="J." last="Paul">J. Paul</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>CR-UK Clinical Triais Unit, Beatson Oncology Centre, Western Infirmary, Dumbarton Road</s1><s2>Glasgow, Scotland GI 1 6NT</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Carty, K" sort="Carty, K" uniqKey="Carty K" first="K." last="Carty">K. Carty</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>CR-UK Clinical Triais Unit, Beatson Oncology Centre, Western Infirmary, Dumbarton Road</s1><s2>Glasgow, Scotland GI 1 6NT</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Kaye, S" sort="Kaye, S" uniqKey="Kaye S" first="S." last="Kaye">S. Kaye</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Royal Marsden Hospital, Downs Road</s1><s2>Sutton, Surrey SM2 5PT</s2><s3>GBR</s3><sZ>10 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">08-0315574</idno><date when="2008">2008</date><idno type="stanalyst">PASCAL 08-0315574 INIST</idno><idno type="RBID">Pascal:08-0315574</idno><idno type="wicri:Area/PascalFrancis/Corpus">003459</idno><idno type="wicri:Area/PascalFrancis/Curation">002B90</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers</title><author><name sortKey="Vasey, P A" sort="Vasey, P A" uniqKey="Vasey P" first="P. A." last="Vasey">P. A. Vasey</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>CR-UK Clinical Triais Unit, Beatson Oncology Centre, Western Infirmary, Dumbarton Road</s1><s2>Glasgow, Scotland GI 1 6NT</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Medicine, University of Queensland</s1><s2>Brisbane Q4029</s2><s3>AUS</s3><sZ>1 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Gore, M" sort="Gore, M" uniqKey="Gore M" first="M." last="Gore">M. Gore</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Royal Marsden Hospital, Fulham Road</s1><s2>London SW15 3SW</s2><s3>GBR</s3><sZ>2 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Wilson, R" sort="Wilson, R" uniqKey="Wilson R" first="R." last="Wilson">R. Wilson</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Belfast City Hospital, Lisbum Road</s1><s2>Belfast, Ireland BT9 7AB</s2><s3>GBR</s3><sZ>3 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Rustin, G" sort="Rustin, G" uniqKey="Rustin G" first="G." last="Rustin">G. Rustin</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Mount Vernon Hospital, Rickmansworth Road</s1><s2>Northwood, Hertfordshire HA6 2RN</s2><s3>GBR</s3><sZ>4 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Gabra, H" sort="Gabra, H" uniqKey="Gabra H" first="H." last="Gabra">H. Gabra</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Western General Hospital, Crewe Road South</s1><s2>Edinburgh, Scotland EH4 2XU</s2><s3>GBR</s3><sZ>5 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Guastalla, J P" sort="Guastalla, J P" uniqKey="Guastalla J" first="J-P." last="Guastalla">J-P. Guastalla</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Centre Léon-Bérard, rue Laennec</s1><s2>69373, Lyon</s2><s3>FRA</s3><sZ>6 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Lauraine, E P" sort="Lauraine, E P" uniqKey="Lauraine E" first="E. P." last="Lauraine">E. P. Lauraine</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Hopital de L'Hotel-Dieu, place du Parvis Notre-Dame</s1><s2>75181 Paris</s2><s3>FRA</s3><sZ>7 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Paul, J" sort="Paul, J" uniqKey="Paul J" first="J." last="Paul">J. Paul</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>CR-UK Clinical Triais Unit, Beatson Oncology Centre, Western Infirmary, Dumbarton Road</s1><s2>Glasgow, Scotland GI 1 6NT</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Carty, K" sort="Carty, K" uniqKey="Carty K" first="K." last="Carty">K. Carty</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>CR-UK Clinical Triais Unit, Beatson Oncology Centre, Western Infirmary, Dumbarton Road</s1><s2>Glasgow, Scotland GI 1 6NT</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Kaye, S" sort="Kaye, S" uniqKey="Kaye S" first="S." last="Kaye">S. Kaye</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Royal Marsden Hospital, Downs Road</s1><s2>Sutton, Surrey SM2 5PT</s2><s3>GBR</s3><sZ>10 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author></analytic><series><title level="j" type="main">British journal of cancer</title><title level="j" type="abbreviated">Br. J. cancer</title><idno type="ISSN">0007-0920</idno><imprint><date when="2008">2008</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">British journal of cancer</title><title level="j" type="abbreviated">Br. J. cancer</title><idno type="ISSN">0007-0920</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic agent</term><term>Cancerology</term><term>Carboplatin</term><term>Clinical trial</term><term>Docetaxel</term><term>Epidermal growth factor receptor</term><term>Erlotinib</term><term>Fallopian tube cancer</term><term>Malignant tumor</term><term>Ovary</term><term>Peritoneum</term><term>Primary</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Docétaxel</term><term>Essai clinique</term><term>Ovaire</term><term>Carboplatine</term><term>Primaire</term><term>Péritoine</term><term>Erlotinib</term><term>Récepteur facteur croissance épiderme</term><term>Cancérologie</term><term>Cancer de la trompe de Fallope</term><term>Tumeur maligne</term><term>Anticancéreux</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The safety and maximum tolerated dose (MTD) of erlotinib with docetaxel/carboplatin were assessed in patients with ovarian cancer. Chemonaive patients received intravenous docetaxel (75 mg m<sup>-2</sup>) and carboplatin (area under the curve 5) on day I of a 3-week cycle, and oral erlotinib at 50 (cohort 1), 100 (cohort 2a) or 75 mg day<sup>-1</sup> (cohort 2b) for up to six cycles. Dose-limiting toxicities were determined in cycle 1. Forty-five patients (median age 59 years) received treatment. Dose-limiting toxicities occurred in 1/5/5 patients (cohorts I /2a/2b). The MTD of erlotinib in this regimen was determined to be 75 mg day<sup>-1</sup> (cohort 2b; the erlotinib dose was escalated to 100mg day<sup>-1</sup> in I I out of 19 patients from cycle 2 onwards). Neutropaenia was the predominant grade 3/4 haematological toxicity (85/100/95% respectively). Common non-haematological toxicities were diarrhoea, fatigue, nausea and rash. There were five complete and seven partial responses in 23 evaluable patients (52% response rate). Docetaxel/carboplatin had no measurable effect on erlotinib pharmacokinetics. In subsequent single-agent maintenance, erlotinib was given at 100-150 mg day<sup>-1</sup>, with manageable toxicity, until tumour progression. Further investigation of erlotinib in epithelial ovarian carcinoma may be warranted, particularly as maintenance therapy.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0007-0920</s0></fA01><fA02 i1="01"><s0>BJCAAI</s0></fA02><fA03 i2="1"><s0>Br. J. cancer</s0></fA03><fA05><s2>98</s2></fA05><fA06><s2>11</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers</s1></fA08><fA11 i1="01" i2="1"><s1>VASEY (P. A.)</s1></fA11><fA11 i1="02" i2="1"><s1>GORE (M.)</s1></fA11><fA11 i1="03" i2="1"><s1>WILSON (R.)</s1></fA11><fA11 i1="04" i2="1"><s1>RUSTIN (G.)</s1></fA11><fA11 i1="05" i2="1"><s1>GABRA (H.)</s1></fA11><fA11 i1="06" i2="1"><s1>GUASTALLA (J-P.)</s1></fA11><fA11 i1="07" i2="1"><s1>LAURAINE (E. P.)</s1></fA11><fA11 i1="08" i2="1"><s1>PAUL (J.)</s1></fA11><fA11 i1="09" i2="1"><s1>CARTY (K.)</s1></fA11><fA11 i1="10" i2="1"><s1>KAYE (S.)</s1></fA11><fA14 i1="01"><s1>CR-UK Clinical Triais Unit, Beatson Oncology Centre, Western Infirmary, Dumbarton Road</s1><s2>Glasgow, Scotland GI 1 6NT</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></fA14><fA14 i1="02"><s1>Division of Medicine, University of Queensland</s1><s2>Brisbane Q4029</s2><s3>AUS</s3><sZ>1 aut.</sZ></fA14><fA14 i1="03"><s1>Royal Marsden Hospital, Fulham Road</s1><s2>London SW15 3SW</s2><s3>GBR</s3><sZ>2 aut.</sZ></fA14><fA14 i1="04"><s1>Belfast City Hospital, Lisbum Road</s1><s2>Belfast, Ireland BT9 7AB</s2><s3>GBR</s3><sZ>3 aut.</sZ></fA14><fA14 i1="05"><s1>Mount Vernon Hospital, Rickmansworth Road</s1><s2>Northwood, Hertfordshire HA6 2RN</s2><s3>GBR</s3><sZ>4 aut.</sZ></fA14><fA14 i1="06"><s1>Western General Hospital, Crewe Road South</s1><s2>Edinburgh, Scotland EH4 2XU</s2><s3>GBR</s3><sZ>5 aut.</sZ></fA14><fA14 i1="07"><s1>Centre Léon-Bérard, rue Laennec</s1><s2>69373, Lyon</s2><s3>FRA</s3><sZ>6 aut.</sZ></fA14><fA14 i1="08"><s1>Hopital de L'Hotel-Dieu, place du Parvis Notre-Dame</s1><s2>75181 Paris</s2><s3>FRA</s3><sZ>7 aut.</sZ></fA14><fA14 i1="09"><s1>Royal Marsden Hospital, Downs Road</s1><s2>Sutton, Surrey SM2 5PT</s2><s3>GBR</s3><sZ>10 aut.</sZ></fA14><fA17 i1="01" i2="1"><s1>Scottish Gynaecological Cancer Trials Group</s1><s3>INC</s3></fA17><fA20><s1>1774-1780</s1></fA20><fA21><s1>2008</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>6925</s2><s5>354000198007140100</s5></fA43><fA44><s0>0000</s0><s1>© 2008 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>1 p.</s0></fA45><fA47 i1="01" i2="1"><s0>08-0315574</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>British journal of cancer</s0></fA64><fA66 i1="01"><s0>GBR</s0></fA66><fC01 i1="01" l="ENG"><s0>The safety and maximum tolerated dose (MTD) of erlotinib with docetaxel/carboplatin were assessed in patients with ovarian cancer. Chemonaive patients received intravenous docetaxel (75 mg m<sup>-2</sup>) and carboplatin (area under the curve 5) on day I of a 3-week cycle, and oral erlotinib at 50 (cohort 1), 100 (cohort 2a) or 75 mg day<sup>-1</sup> (cohort 2b) for up to six cycles. Dose-limiting toxicities were determined in cycle 1. Forty-five patients (median age 59 years) received treatment. Dose-limiting toxicities occurred in 1/5/5 patients (cohorts I /2a/2b). The MTD of erlotinib in this regimen was determined to be 75 mg day<sup>-1</sup> (cohort 2b; the erlotinib dose was escalated to 100mg day<sup>-1</sup> in I I out of 19 patients from cycle 2 onwards). Neutropaenia was the predominant grade 3/4 haematological toxicity (85/100/95% respectively). Common non-haematological toxicities were diarrhoea, fatigue, nausea and rash. There were five complete and seven partial responses in 23 evaluable patients (52% response rate). Docetaxel/carboplatin had no measurable effect on erlotinib pharmacokinetics. In subsequent single-agent maintenance, erlotinib was given at 100-150 mg day<sup>-1</sup>, with manageable toxicity, until tumour progression. Further investigation of erlotinib in epithelial ovarian carcinoma may be warranted, particularly as maintenance therapy.</s0></fC01><fC02 i1="01" i2="X"><s0>002B04</s0></fC02><fC02 i1="02" i2="X"><s0>002B20C02</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Docétaxel</s0><s2>NK</s2><s2>FR</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Docetaxel</s0><s2>NK</s2><s2>FR</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Docetaxel</s0><s2>NK</s2><s2>FR</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Essai clinique</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Clinical trial</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Ensayo clínico</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Ovaire</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Ovary</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Ovario</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Carboplatine</s0><s2>NK</s2><s2>FR</s2><s5>04</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Carboplatin</s0><s2>NK</s2><s2>FR</s2><s5>04</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Carboplatino</s0><s2>NK</s2><s2>FR</s2><s5>04</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Primaire</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Primary</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Primario</s0><s5>05</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Péritoine</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Peritoneum</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Peritoneo</s0><s5>06</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Erlotinib</s0><s2>FR</s2><s5>07</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Erlotinib</s0><s2>FR</s2><s5>07</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Erlotinib</s0><s2>FR</s2><s5>07</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Récepteur facteur croissance épiderme</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Epidermal growth factor receptor</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Receptor del factor de crecimiento epidérmico</s0><s5>08</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Cancérologie</s0><s5>09</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Cancerology</s0><s5>09</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Cancerología</s0><s5>09</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Cancer de la trompe de Fallope</s0><s2>NM</s2><s5>10</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Fallopian tube cancer</s0><s2>NM</s2><s5>10</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Cáncer de falopio del tubo</s0><s2>NM</s2><s5>10</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Tumeur maligne</s0><s2>NM</s2><s5>13</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Malignant tumor</s0><s2>NM</s2><s5>13</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>Tumor maligno</s0><s2>NM</s2><s5>13</s5></fC03><fC03 i1="12" i2="X" l="FRE"><s0>Anticancéreux</s0><s5>25</s5></fC03><fC03 i1="12" i2="X" l="ENG"><s0>Antineoplastic agent</s0><s5>25</s5></fC03><fC03 i1="12" i2="X" l="SPA"><s0>Anticanceroso</s0><s5>25</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Cancer</s0><s2>NM</s2></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Cancer</s0><s2>NM</s2></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Cáncer</s0><s2>NM</s2></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Antimitotique</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Antimitotic</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Antimitótico</s0><s5>37</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Dérivé du taxane</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Taxane derivatives</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Taxane derivado</s0><s5>38</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Platine II Complexe</s0><s2>NC</s2><s2>NA</s2><s5>39</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Platinum II Complexes</s0><s2>NC</s2><s2>NA</s2><s5>39</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Platino II Complejo</s0><s2>NC</s2><s2>NA</s2><s5>39</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Inhibiteur enzyme</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Enzyme inhibitor</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Inhibidor enzima</s0><s5>40</s5></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Dérivé de la quinazoline</s0><s2>FR</s2><s5>41</s5></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Quinazoline derivatives</s0><s2>FR</s2><s5>41</s5></fC07><fC07 i1="07" i2="X" l="FRE"><s0>Protein-tyrosine kinase</s0><s2>FE</s2><s5>42</s5></fC07><fC07 i1="07" i2="X" l="ENG"><s0>Protein-tyrosine kinase</s0><s2>FE</s2><s5>42</s5></fC07><fC07 i1="07" i2="X" l="SPA"><s0>Protein-tyrosine kinase</s0><s2>FE</s2><s5>42</s5></fC07><fC07 i1="08" i2="X" l="FRE"><s0>Transferases</s0><s2>FE</s2></fC07><fC07 i1="08" i2="X" l="ENG"><s0>Transferases</s0><s2>FE</s2></fC07><fC07 i1="08" i2="X" l="SPA"><s0>Transferases</s0><s2>FE</s2></fC07><fC07 i1="09" i2="X" l="FRE"><s0>Enzyme</s0><s2>FE</s2></fC07><fC07 i1="09" i2="X" l="ENG"><s0>Enzyme</s0><s2>FE</s2></fC07><fC07 i1="09" i2="X" l="SPA"><s0>Enzima</s0><s2>FE</s2></fC07><fC07 i1="10" i2="X" l="FRE"><s0>Inhibiteur de la tyrosine kinase</s0><s5>43</s5></fC07><fC07 i1="10" i2="X" l="ENG"><s0>Tyrosine kinase inhibitor</s0><s5>43</s5></fC07><fC07 i1="10" i2="X" l="SPA"><s0>Inhibidor tyrosine kinase</s0><s5>43</s5></fC07><fC07 i1="11" i2="X" l="FRE"><s0>Appareil génital femelle</s0><s5>45</s5></fC07><fC07 i1="11" i2="X" l="ENG"><s0>Female genital system</s0><s5>45</s5></fC07><fC07 i1="11" i2="X" l="SPA"><s0>Aparato genital hembra</s0><s5>45</s5></fC07><fC07 i1="12" i2="X" l="FRE"><s0>Pathologie de l'appareil génital femelle</s0><s5>46</s5></fC07><fC07 i1="12" i2="X" l="ENG"><s0>Female genital diseases</s0><s5>46</s5></fC07><fC07 i1="12" i2="X" l="SPA"><s0>Aparato genital hembra patología</s0><s5>46</s5></fC07><fC07 i1="13" i2="X" l="FRE"><s0>Pathologie de la trompe de Fallope</s0><s5>47</s5></fC07><fC07 i1="13" i2="X" l="ENG"><s0>Fallopian tube pathology</s0><s5>47</s5></fC07><fC07 i1="13" i2="X" l="SPA"><s0>Trompa Falopio patología</s0><s5>47</s5></fC07><fN21><s1>196</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B90 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 002B90 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:08-0315574
|texte= A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
}}
| This area was generated with Dilib version V0.6.33. |  |